{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:38:45Z","timestamp":1722559125713},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"DOI":"10.7759\/cureus.65960","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:29:45Z","timestamp":1722533385000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment Approach for Advanced Systemic Light Chain Amyloidosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Mohamad Ali M","family":"Hachem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadir M","family":"Nasreddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solay","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab M","family":"Hammoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajih A","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini G","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018, 4:38. 10.1038\/s41572-018-0034-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00396","article-title":"Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation","volume":"19","author":"Dima D","year":"2023","unstructured":"Dima D, Mazzoni S, Anwer F, Khouri J, Samaras C, Valent J, Williams L. Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation. JCO Oncol Pract. 2023, 19:265-75. 10.1200\/OP.22.00396","journal-title":"JCO Oncol Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01830-z","article-title":"Diagnosis and treatment of AL amyloidosis","volume":"83","author":"Palladini G","year":"2023","unstructured":"Palladini G, Milani P. Diagnosis and treatment of AL amyloidosis. Drugs. 2023, 83:203-16. 10.1007\/s40265-022-01830-z","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1070","article-title":"Light chain amyloidosis: epidemiology, staging, and prognostication","volume":"18","author":"Baker KR","year":"2022","unstructured":"Baker KR. Light chain amyloidosis: epidemiology, staging, and prognostication. Methodist Debakey Cardiovasc J. 2022, 18:27-35. 10.14797\/mdcvj.1070","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02414-6","article-title":"Global epidemiology of amyloid light-chain amyloidosis","volume":"17","author":"Kumar N","year":"2022","unstructured":"Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022, 17:278. 10.1186\/s13023-022-02414-6","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.5.5","article-title":"Immunoglobulin light-chain amyloidosis: clinical presentations and diagnostic approach","volume":"10","author":"Hwa YL","year":"2019","unstructured":"Hwa YL, Fogaren T, Sams A, Faller DV, Stull DM, Thuenemann S, Mendelson L. Immunoglobulin light-chain amyloidosis: clinical presentations and diagnostic approach. J Adv Pract Oncol. 2019, 10:470-81. 10.6004\/jadpro.2019.10.5.5","journal-title":"J Adv Pract Oncol"},{"key":"ref7","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines. 2023. p. 29 Systematic Light Chain Amyloidosis - version 2.2023. https.\/\/www.nccn.org\/guidelines\/recently-published-guidelines."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini G","year":"2020","unstructured":"Palladini G, Kastritis E, Maurer MS, et al.. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020, 136:71-80. 10.1182\/blood.2019004460","journal-title":"Blood"},{"key":"ref9","unstructured":"American Society of Hematology. First-of-its-Kind Study Reveals Predictive Factors for Outcomes of Advanced Stage AL Amyloidosis. https.\/\/www.hematology.org\/newsroom\/press-releases\/2023\/first-of-its-kind-study-reveals-predictive-factors-for-outcom...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010324","article-title":"Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis","volume":"7","author":"Gustine JN","year":"2023","unstructured":"Gustine JN, Staron A, Mendelson L, et al.. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv. 2023, 7:6080-91. 10.1182\/bloodadvances.2023010324","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron A","year":"2021","unstructured":"Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, Sanchorawala V. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021, 11:139. 10.1038\/s41408-021-00529-w","journal-title":"Blood Cancer J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini G","year":"2017","unstructured":"Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program. 2017, 2017:1-12. 10.1182\/asheducation-2017.1.1","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar S","year":"2010","unstructured":"Kumar S, Dispenzieri A, Katzmann JA, et al.. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010, 116:5126-9. 10.1182\/blood-2010-06-290668","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0047-0","article-title":"Serum amyloid A - a review","volume":"24","author":"Sack GH Jr","year":"2018","unstructured":"Sack GH Jr. Serum amyloid A - a review. Mol Med. 2018, 24:46. 10.1186\/s10020-018-0047-0","journal-title":"Mol Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar S","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al.. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012, 30:989-95. 10.1200\/JCO.2011.38.5724","journal-title":"J Clin Oncol"},{"key":"ref16","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in\u00a0Oncology. Systemic Light Chain Amyloidosis. (2024). https:\/\/www.nccn.org\/guidelines\/category_1."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05090-z","article-title":"Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA","volume":"102","author":"Suzuki K","year":"2023","unstructured":"Suzuki K, Wechalekar AD, Kim K, et al.. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA. Ann Hematol. 2023, 102:863-76. 10.1007\/s00277-023-05090-z","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253177-treatment-approach-for-advanced-systemic-light-chain-amyloidosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:29:56Z","timestamp":1722533396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253177-treatment-approach-for-advanced-systemic-light-chain-amyloidosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.65960","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}